Replies to post #20479 on Vilacto Bio Inc. (fka VIBI)

[_SuperPennies_]

$VIBI *********Industry is also betting on the therapeutic potential of IDPs. Biotechnology company IDP Pharma is developing a type of protein inhibitor to treat multiple myeloma and small-cell lung cancer. Graffinity Pharmaceuticals, now part of NovAliX, has identified small molecules to target the disordered protein tau, which is involved in Alzheimer’s pathology. Cantabio Pharmaceuticals is on the hunt for small molecules to stabilize IDPs involved in neurodegeneration. And a new company called Dewpoint Therapeutics is exploring the idea that droplets and their disordered components, because of the way they bring molecules together for enhanced reactions, could be used as drug targets.* It is increasingly likely that in the next three to five years these once “undruggable” proteins will end up in the crosshairs of pharmaceutical development.